Genprex (GNPX) Competitors

Genprex logo
$1.45 -0.22 (-13.17%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$1.48 +0.03 (+1.72%)
As of 11/20/2026 06:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GNPX vs. LTRN, BLRX, FBLG, ALZN, and APRE

Should you buy Genprex stock or one of its competitors? Genprex's main competitors and comparable companies include Lantern Pharma (LTRN), BioLineRx (BLRX), FibroBiologics (FBLG), Alzamend Neuro (ALZN), and Aprea Therapeutics (APRE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Genprex compare to Lantern Pharma?

Lantern Pharma (NASDAQ:LTRN) and Genprex (NASDAQ:GNPX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Genprex's return on equity of -126.83% beat Lantern Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Lantern PharmaN/A -793.54% -183.28%
Genprex N/A -126.83%-104.02%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lantern Pharma
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Genprex
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

28.6% of Lantern Pharma shares are owned by institutional investors. Comparatively, 14.1% of Genprex shares are owned by institutional investors. 8.8% of Lantern Pharma shares are owned by insiders. Comparatively, 0.3% of Genprex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Lantern Pharma has a beta of 2.48, indicating that its share price is 148% more volatile than the broader market. Comparatively, Genprex has a beta of -0.95, indicating that its share price is 195% less volatile than the broader market.

Lantern Pharma is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lantern PharmaN/AN/A-$17.12M-$1.60N/A
GenprexN/AN/A-$16.23M-$28.77N/A

In the previous week, Lantern Pharma had 4 more articles in the media than Genprex. MarketBeat recorded 5 mentions for Lantern Pharma and 1 mentions for Genprex. Genprex's average media sentiment score of 0.00 beat Lantern Pharma's score of -1.07 indicating that Genprex is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lantern Pharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Negative
Genprex
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Lantern Pharma beats Genprex on 6 of the 11 factors compared between the two stocks.

How does Genprex compare to BioLineRx?

Genprex (NASDAQ:GNPX) and BioLineRx (NASDAQ:BLRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

14.1% of Genprex shares are owned by institutional investors. Comparatively, 1.6% of BioLineRx shares are owned by institutional investors. 0.3% of Genprex shares are owned by insiders. Comparatively, 1.1% of BioLineRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genprex
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
BioLineRx
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Genprex has a beta of -0.95, meaning that its stock price is 195% less volatile than the broader market. Comparatively, BioLineRx has a beta of 1.64, meaning that its stock price is 64% more volatile than the broader market.

In the previous week, BioLineRx had 3 more articles in the media than Genprex. MarketBeat recorded 4 mentions for BioLineRx and 1 mentions for Genprex. Genprex's average media sentiment score of 0.00 equaled BioLineRx'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Genprex
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
BioLineRx
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

BioLineRx has higher revenue and earnings than Genprex. BioLineRx is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GenprexN/AN/A-$16.23M-$28.77N/A
BioLineRx$1.39M3.45-$1.17M-$1.69N/A

Genprex has a net margin of 0.00% compared to BioLineRx's net margin of -502.08%. BioLineRx's return on equity of -34.80% beat Genprex's return on equity.

Company Net Margins Return on Equity Return on Assets
GenprexN/A -126.83% -104.02%
BioLineRx -502.08%-34.80%-18.27%

Summary

BioLineRx beats Genprex on 8 of the 11 factors compared between the two stocks.

How does Genprex compare to FibroBiologics?

Genprex (NASDAQ:GNPX) and FibroBiologics (NASDAQ:FBLG) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

14.1% of Genprex shares are held by institutional investors. 0.3% of Genprex shares are held by insiders. Comparatively, 7.3% of FibroBiologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Genprex has a beta of -0.95, suggesting that its stock price is 195% less volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market.

In the previous week, FibroBiologics had 5 more articles in the media than Genprex. MarketBeat recorded 6 mentions for FibroBiologics and 1 mentions for Genprex. FibroBiologics' average media sentiment score of 0.57 beat Genprex's score of 0.00 indicating that FibroBiologics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Genprex
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
FibroBiologics
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

FibroBiologics has a consensus price target of $72.00, indicating a potential upside of 10,112.77%. Given FibroBiologics' stronger consensus rating and higher probable upside, analysts plainly believe FibroBiologics is more favorable than Genprex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genprex
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
FibroBiologics
2 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.80

Genprex's return on equity of -126.83% beat FibroBiologics' return on equity.

Company Net Margins Return on Equity Return on Assets
GenprexN/A -126.83% -104.02%
FibroBiologics N/A -431.79%-217.07%

FibroBiologics is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GenprexN/AN/A-$16.23M-$28.77N/A
FibroBiologicsN/AN/A-$18.65M-$2.97N/A

Summary

FibroBiologics beats Genprex on 8 of the 13 factors compared between the two stocks.

How does Genprex compare to Alzamend Neuro?

Alzamend Neuro (NASDAQ:ALZN) and Genprex (NASDAQ:GNPX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Alzamend Neuro has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market. Comparatively, Genprex has a beta of -0.95, suggesting that its share price is 195% less volatile than the broader market.

In the previous week, Genprex had 1 more articles in the media than Alzamend Neuro. MarketBeat recorded 1 mentions for Genprex and 0 mentions for Alzamend Neuro. Alzamend Neuro's average media sentiment score of 0.00 equaled Genprex'saverage media sentiment score.

Company Overall Sentiment
Alzamend Neuro Neutral
Genprex Neutral

Alzamend Neuro presently has a consensus price target of $28.00, indicating a potential upside of 3,509.18%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, equities research analysts plainly believe Alzamend Neuro is more favorable than Genprex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alzamend Neuro
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Genprex
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

49.6% of Alzamend Neuro shares are owned by institutional investors. Comparatively, 14.1% of Genprex shares are owned by institutional investors. 1.4% of Alzamend Neuro shares are owned by insiders. Comparatively, 0.3% of Genprex shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Alzamend Neuro is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alzamend NeuroN/AN/A-$8.77M-$2.30N/A
GenprexN/AN/A-$16.23M-$28.77N/A

Genprex's return on equity of -126.83% beat Alzamend Neuro's return on equity.

Company Net Margins Return on Equity Return on Assets
Alzamend NeuroN/A -277.88% -184.20%
Genprex N/A -126.83%-104.02%

Summary

Alzamend Neuro beats Genprex on 8 of the 12 factors compared between the two stocks.

How does Genprex compare to Aprea Therapeutics?

Aprea Therapeutics (NASDAQ:APRE) and Genprex (NASDAQ:GNPX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

In the previous week, Aprea Therapeutics had 3 more articles in the media than Genprex. MarketBeat recorded 4 mentions for Aprea Therapeutics and 1 mentions for Genprex. Aprea Therapeutics' average media sentiment score of 0.32 beat Genprex's score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aprea Therapeutics
0 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Genprex
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Aprea Therapeutics is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aprea TherapeuticsN/AN/A-$12.60M-$0.70N/A
GenprexN/AN/A-$16.23M-$28.77N/A

34.2% of Aprea Therapeutics shares are held by institutional investors. Comparatively, 14.1% of Genprex shares are held by institutional investors. 10.5% of Aprea Therapeutics shares are held by company insiders. Comparatively, 0.3% of Genprex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Aprea Therapeutics currently has a consensus price target of $2.80, indicating a potential upside of 1,122.71%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Aprea Therapeutics is more favorable than Genprex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aprea Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Genprex
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Aprea Therapeutics' return on equity of -44.69% beat Genprex's return on equity.

Company Net Margins Return on Equity Return on Assets
Aprea TherapeuticsN/A -44.69% -39.12%
Genprex N/A -126.83%-104.02%

Aprea Therapeutics has a beta of 1.74, meaning that its share price is 74% more volatile than the broader market. Comparatively, Genprex has a beta of -0.95, meaning that its share price is 195% less volatile than the broader market.

Summary

Aprea Therapeutics beats Genprex on 12 of the 13 factors compared between the two stocks.

Get Genprex News Delivered to You Automatically

Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GNPX vs. The Competition

MetricGenprexBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.94M$3.92B$7.44B$10.86B
Dividend YieldN/A3.79%2.51%4.62%
P/E Ratio-0.0523.0732.5628.68
Price / SalesN/A14.927.725.17
Price / CashN/A21.9220.2520.77
Price / Book0.144.124.343.51
Net Income-$16.23M-$24.08M$3.51B$394.12M
7 Day Performance-30.29%-9.85%-8.07%-8.97%
1 Month Performance-26.77%-12.77%-10.29%-11.61%
1 Year Performance-97.80%-7.99%-4.70%-11.21%

Genprex Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GNPX
Genprex
0.2564 of 5 stars
$1.45
-13.2%
N/A-97.8%$1.94MN/AN/A13
LTRN
Lantern Pharma
0.2761 of 5 stars
$0.44
-5.3%
N/A-91.9%$6.51MN/AN/A16
BLRX
BioLineRx
0.2741 of 5 stars
$1.29
-4.7%
N/A-70.3%$6.40M$1.18MN/A22
FBLG
FibroBiologics
1.6512 of 5 stars
$0.95
-2.0%
$73.00
+7,600.4%
-89.6%$6.31MN/AN/A15
ALZN
Alzamend Neuro
2.3557 of 5 stars
$1.29
-0.8%
$28.00
+2,070.5%
-60.4%$6.23MN/AN/A6

Related Companies and Tools


This page (NASDAQ:GNPX) was last updated on 11/22/2026 by MarketBeat.com Staff.
From Our Partners